Martin Heidinger, Michael Knauer, Christoph Tausch, Walter P Weber
Axillary surgery in patients with breast cancer has been a history of de-escalation; however, surgery for clinically node-positive breast cancer remained at the dogmatic level of axillary lymph node dissection (ALND). In these patients, currently the only way to avoid ALND is neoadjuvant systemic treatment (NST) with nodal pathologic complete response (pCR) as diagnosed by selective lymph node removal. However, pCR rates are highly dependent on tumor biology, with luminal tumors being most present yet showing the lowest pCR rates...
March 8, 2023: Breast: Official Journal of the European Society of Mastology
Stephanie Downs-Canner, Elizabeth A Mittendorf
No abstract text is available yet for this article.
March 10, 2023: Annals of Surgical Oncology
Elisabeth Solmunde, Anne Mette Falstie-Jensen, Ebbe L Lorenzen, Marianne Ewertz, Kristin V Reinertsen, Olaf M Dekkers, Deirdre P Cronin-Fenton
OBJECTIVE: Breast cancer and breast cancer-directed radiation therapy (RT) may increase the risk of late effects, such as hypothyroidism. We conducted a systematic review and meta-analysis to investigate the association between breast cancer, RT, and risk of hypothyroidism in breast cancer survivors. METHODS: Through February 2022, we searched PubMed, EMBASE, and references of relevant articles, to identify papers on breast cancer and breast cancer-directed RT and subsequent risk of hypothyroidism...
February 18, 2023: Breast: Official Journal of the European Society of Mastology
Shuyi Chen, Christopher Thacker, Shengxuan Wang, Katelyn A Young, Rebecca L Hoffman, Joseph A Blansfield
INTRODUCTION: Oncotype Dx (ODX) is a genetic assay that analyzes tumor recurrence risk and provides chemotherapy recommendations for T1-T2 stage, hormone receptor-positive, human epidermal growth factor receptor-negative, and nodal-negative breast cancer patients. Despite its established validity, the utilization of this assay is suboptimal. The study aims to evaluate factors that are associated with adherence rate with the testing guidelines and examine changes in utilization trends...
February 7, 2023: Journal of Surgical Research
Ondine Dufour, Gilles Houvenaeghel, Jean-Marc Classe, Monique Cohen, Christelle Faure, Chafika Mazouni, Marie-Pierre Chauvet, Eva Jouve, Emile Darai, Anne-Sophie Azuar, Pierre Gimbergues, Anthony Gonçalves, Alexandre de Nonneville
BACKGROUND: There is a scarcity of data exploring early breast cancer (eBC) in very young patients. We assessed shared and intrinsic prognostic factors in a large cohort of patients aged ≤35, compared to a control group aged 36 to 50. METHODS: Patients ≤50 were retrospectively identified from a multicentric cohort of 23,134 eBC patients who underwent primary surgery between 1990 and 2014. Multivariate Cox analyses for DFS and OS were built. To assess the independent impact of age, 1 to 3 case-control analysis was performed by matching ≤35 and 36-50 years patients...
February 8, 2023: Breast: Official Journal of the European Society of Mastology
Subarnarekha Chatterji, Emma Krzoska, Christopher W Thoroughgood, John Saganty, Peng Liu, Beatrix Elsberger, Rasha Abu-Eid, Valerie Speirs
Although similar phenotypically, there is evidence that male and female breast cancer differ in their molecular landscapes. In this systematic review, we consolidated all existing prognostic biomarker data in male breast cancer spanning genetics, transcriptomics, proteomics, and epigenetics, and phenotypic features of prognostic value from articles published over a 29-year period (March 16, 1992, to May 1, 2021). We identified knowledge gaps in the existing literature, discussed limitations of the included studies, and outlined potential approaches for translational biomarker discovery and validation in male breast cancer...
February 2023: Lancet Oncology
A H M Safayet Ullah Prodhan, Dewan Zubaer Islam, Shahad Saif Khandker, Mohd Raeed Jamiruddin, Adnan Abdullah, Brian Godman, Sylvia Opanga, Santosh Kumar, Paras Sharma, Nihad Adnan, Alice Pisana, Mainul Haque
During the COVID-19 pandemic, several priority diseases were not getting sufficient attention. Whilst breast cancer is a fatal disease affecting millions worldwide, identification and management of these patients did not initially attract critical attention to minimize the impact of lockdown, post-lockdown, and other measures. Breast cancer patients' conditions may not remain stable without proper care, worsening their prognosis. Proper care includes the timely instigation of surgery, systemic therapy, and psychological support...
2023: Breast Cancer: Targets and Therapy
Lauren Gleckler, Nikita Roy, Michelle Bernstein, Tara M Balija, Caroline LaPlaca, Elisa Port, Stephanie Bernik
BACKGROUND: Breast MRI has been associated with significant rates of false positive findings. We aimed to determine the frequency of extra-mammary findings (EMFs) in newly diagnosed breast cancer patients on breast MRI with contrast and assess the significance of these findings and need for additional imaging and follow up. STUDY DESIGN: Retrospective review of patients diagnosed with breast cancer from October 2018 - October 2019 was performed. Clinico-pathologic features were collected, including type of breast cancer, size, stage, and whether the patients had a breast MRI...
January 31, 2023: Journal of the American College of Surgeons
Sukh Makhnoon, Angelica M Gutierrez Barrera, Roland Bassett, Aimaz Afrough, Isabelle Bedrosian, Banu K Arun
BACKGROUND: Patients with unilateral breast cancer carrying pathogenic variants in BRCA1/2 have the option to undergo contralateral prophylactic mastectomy (CPM). However, differences in CPM use and survival outcomes following CPM are poorly understood in this high-risk population, in part due to a lack of data from contemporary clinical cohorts. The objective of this study was to evaluate post-CPM overall survival (OS) and related racial/ethnic differences in a contemporary clinical cohort...
2022: Breast Journal
Hong-Lu Zhou, Dan-Dan Chen
BACKGROUND: Triple-negative breast cancer (TNBC) was a particularly aggressive subtype of breast cancer associated with poor prognosis. This retrospective study was conducted to investigate the clinical features, prognostic factors, and benefits of surgery of patients with TNBC. METHODS: From 2010 to 2015, 33654 female patients with TNBC were obtained from the Surveillance, Epidemiology, and End Results (SEER) database. The patients were randomly divided into the training and validation cohorts...
January 11, 2023: Clinical Breast Cancer
F Miglietta, A Fabi, D Generali, M V Dieci, G Arpino, G Bianchini, S Cinieri, P F Conte, G Curigliano, M De Laurentis, L Del Mastro, S De Placido, A Gennari, F Puglisi, A Zambelli, F Perrone, V Guarneri
Triple-negative (TN) metastatic breast cancer (mBC) represents the most challenging scenario withing mBC framework, and it has been only slightly affected by the tremendous advancements in terms of drug availability and survival prolongation we have witnessed in the last years for advanced disease. However, although chemotherapy still represents the mainstay of TN mBC management, in the past years, several novel effective agents have been developed and made available in the clinical practice setting. Within this framework, a panel composed of a scientific board of 17 internationally recognized breast oncologists and 42 oncologists working within local spoke centers, addressed 26 high-priority statements, including grey areas, regarding the management of TN mBC...
March 2023: Cancer Treatment Reviews
Khava I E Ibragimova, Sandra M E Geurts, Marissa Meegdes, Frans Erdkamp, Joan B Heijns, Jolien Tol, Birgit E P J Vriens, Marcus W Dercksen, Kirsten N A Aaldering, Manon J A E Pepels, Linda van de Winkel, Natascha A J B Peters, Nathalie J A Teeuwen-Dedroog, Ingeborg J H Vriens, Vivianne C G Tjan-Heijnen
PURPOSE: We assessed the systemic treatment choices and outcomes in patients diagnosed with human epidermal growth factor receptor-2-positive (HER2 +) advanced breast cancer (ABC), for the first four lines of systemic therapy and by hormone receptor (HR) status. METHODS: We identified 330 patients diagnosed with HER2 + ABC in 2013-2018 in the Southeast of The Netherlands, of whom 64% with HR + /HER2 + and 36% with HR-/HER2 + disease...
January 12, 2023: Breast Cancer Research and Treatment
Robyn N Rubenstein, Jonas A Nelson, Saïd C Azoury, Meghana G Shamsunder, Kathryn Haglich, Shen Yin, Carrie S Stern, Evan Matros
BACKGROUND: National databases are a rich source of epidemiologic data for breast surgical oncology research. However, these databases differ in the demographic, surgical, and oncologic variables provided. This study aimed to compare the strengths and limitations of four national databases in the context of breast surgical oncology research. METHODS: The study comprised a descriptive analysis of four national databases (the National Surgical Quality Improvement Program [NSQIP], the Nationwide Inpatient Sample [NIS], the Surveillance, Epidemiology and End Results [SEER] program, and the National Cancer Database [NCDB]) to assess their strengths and limitations in the context of breast surgical oncology...
January 4, 2023: Annals of Surgical Oncology
Michael Ha, Ledibabari M Ngaage, Emily R Finkelstein, Marissa Klein, Annie Yanga, Shannon M Colohan, Suliat M Nurudeen, Julia H Terhune, Sheri Slezak, Yvonne M Rasko
BACKGROUND: Breast cancer is associated with a multitude of risk factors, such as genetic predisposition and mutations, family history, personal medical history, or previous radiotherapy. A prophylactic mastectomy (PM) may be considered a suitable risk-reducing procedure in some cases. However, there are significant discrepancies between national society recommendations and insurance company requirements for PM. MATERIALS AND METHODS: The authors conducted a cross-sectional analysis of insurance policies for a PM...
December 5, 2022: Clinical Breast Cancer
Emanuele Zarba Meli, Anna De Santis, Giuliana Cortese, Elena Manna, Tiziana Mastropietro, Massimo La Pinta, Andrea Loreti, Floriana Arelli, Paola Scavina, Mauro Minelli, Angela Damiana Andrulli, Leopoldo Costarelli, Laura Broglia, Tatiana Ponzani, Lucio Fortunato
BACKGROUND: Nipple-sparing mastectomy (NSM) is increasingly used for women with breast cancer who are not candidates for conservative surgery. The authors previously reported satisfying results with NSM after neoadjuvant chemotherapy (NACT). METHODS: From 2010 to 2020, 1072 women underwent mastectomy at the authors' institution. In this group, 433 NSMs were performed (40%). The only contraindications to NSM were close proximity to the nipple-areola complex (NAC), bloody discharge, and Paget disease...
January 4, 2023: Annals of Surgical Oncology
Quratul Ain, Caroline Richardson, Miriam Mutebi, Angela George, Zoe Kemp, Jennifer E Rusby
BACKGROUND: Germline pathogenic variants mutations) in the BRCA1 and BRCA2 genes cause an increased risk of breast cancer and ovarian cancer. Mainstream cancer genetic testing (MCG) was introduced for breast cancer patients in our unit in 2013. Non-geneticist clinicians have been trained to offer genetic testing during initial treatment planning. We assessed the impact of timely test results on surgical decision-making. METHODS: Women who had undergone mainstream genetic testing for breast cancer between September 2013 and September 2018 were identified from a prospective database...
December 6, 2022: Breast: Official Journal of the European Society of Mastology
Claudette Falato, Francesco Schettini, Tomás Pascual, Fara Brasó-Maristany, Aleix Prat
Traditionally, the classification of breast cancer relies on the expression of immunohistochemical (IHC) biomarkers readily available in clinical practice. Using highly standardized and reproducible assays across patient cohorts, intrinsic molecular subtypes of breast cancer - also called "intrinsic subtypes" (IS) - have been identified based on the expression of 50 genes. Although IHC-based subgroups and IS moderately correlate to each other, they are not superimposable. In fact, non-luminal biology has been detected in a substantial proportion (5-20%) of hormone receptor-positive (HoR+) tumors, has prognostic value, and identifies reduced and increased sensitivity to endocrine therapy and chemotherapy, respectively...
January 2023: Cancer Treatment Reviews
Fausto Petrelli, Valentina Bertaglia, Maria Chiara Parati, Karen Borgonovo, Pushpamali De Silva, Andrea Luciani, Silvia Novello, Mario Scartozzi, Leisha A Emens, Cinzia Solinas
The current standard of care for resected early-stage triple negative breast cancer (TNBC) patients who did not receive systemic preoperative therapy is adjuvant anthracycline- and taxane-based chemotherapy (CT). A network meta-analysis (NMA) of randomized controlled trials (phase III) enrolling patients with resected stage I-III TNBC comparing adjuvant regimens was performed. Overall survival (OS) and disease-free survival (DFS) data were extracted. A total of 27 phase III clinical trials were selected including 15,242 TNBC patients...
December 15, 2022: Breast: Official Journal of the European Society of Mastology
George E Naoum, Alphonse G Taghian
No abstract text is available yet for this article.
December 20, 2022: Journal of Clinical Oncology
Jana de Boniface, Robert Szulkin, Anna L V Johansson
BACKGROUND: Mastectomy rates in breast cancer are higher in older patients. The aim was to compare postoperative complication rates after breast-conserving surgery (BCS) to mastectomy in women aged 70-79 and older than 80 years versus those aged 50-69 years, and to evaluate survival effects. METHODS: This population-based cohort included women aged 50 years and older with invasive breast cancer T1-3 N0-3 M0 operated on in Sweden 2008-2017. Major surgical and medical 30-day postoperative complications were assessed in adjusted logistic regression models...
December 13, 2022: British Journal of Surgery
2022-12-22 21:29:35
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.